Chinese Hepatolgy ›› 2022, Vol. 27 ›› Issue (5): 526-530.

• Liver Fibrosis & Cirrhosis • Previous Articles     Next Articles

Risk factors of rebleeding after endoscopic treatment for esophagogastric varices in liver cirrhosis patients

FANG Qing-qing1, CHEN Ying1, CHEN Wei1, JIAN You-rong1, LI Yu1, ZHU Zi-hua1, SHEN Dan Jie1, CHEN Shi-yao, LI Feng1,2   

  1. 1. Department of Gastroenterology,Minhang Hospital, Fudan University, Shanghai 201199,China;
    2.Department of Gastroenterology,Zhongshan Hospital,Fudan University,Shanghai 200032,China
  • Received:2022-02-25 Online:2022-05-31 Published:2022-07-13
  • Contact: LI Feng, Email: 13661654285@163.com

Abstract: Objective To investigate the rebleeding rate and the risk factors of rebleeding after endoscopic treatment for esophagogastric varices in liver cirrhosis patients. Methods Retrospective analysis the clinical data of patients who with liver cirrhosis and accept esophageal variceal ligation and/or gastric variceal obliteration treatment for the first time from June 2018 to June 2021, and hospitalized in the Department of Gastroenterology of Minhang Hospital, Fudan University. According to whether there was bleeding during the follow-up period after treatment, they were divided into bleeding group and non bleeding group. The clinical features, laboratory results, imaging findings, hemodynamic parameters and endoscopic treatment were compared between the two groups. Cox regression model was used to explore the independent risk factors of bleeding after endoscopic treatment of varices. Results A total of 75 patients were included, of which 15 (20%) had bleeding during the follow-up after treatment. Compared with the non bleeding group, 14 of the 54 patients who with gastrointestinal bleeding before endoscopic treatment had bleeding after treatment, the bleeding rate was 25.93%, P=0.04. There were 24 cases complicated with portal vein thrombosis, while 8 cases were bleeding after treatment, the bleeding rate was 33.33%, P=0.048. In 35 cases of cirrhosis after hepatitis B, 11 cases had bleeding after treatment, the bleeding rate was 31.43%, P=0.021. And 24 cases of child a, 4 cases of bleeding after treatment, 47 cases of Child B, 8 cases of bleeding after treatment, 4 cases of child C, 3 cases of bleeding after treatment, P=0.018. Gastrointestinal bleeding occurred before endoscopic treatment, the portal vein thrombosis, cirrhosis after hepatitis B and Child-Pugh are risk factors for bleeding after endoscopic treatment, the difference between the two groups was statistically significant. Cox regression analysis showed that Child-Pugh grade (95%CI=1.273~12.879, HR=4.0487, P=0.018) was an independent risk factor for bleeding during follow-up after endoscopic treatment of varices. Conclusion Child Pugh grade is an independent risk factor for bleeding after endoscopic treatment in patients with liver cirrhosis and esophagogastric varices. Endoscopic treatment for gastroesophageal varices in patients who with poor liver function should be cautious.

Key words: Cirrhosis, Esophagogastric varices, Endoscopic treatment, Rebleeding